Eli Lilly plans to invest over USD one billion in India to enhance its manufacturing and supply capacity through partnerships with local drugmakers.
The investment aims to support production of key medicines for obesity, diabetes, Alzheimer’s, cancer, and autoimmune diseases. Despite not having its own manufacturing facility in India, Lilly is actively collaborating with contract manufacturers and setting up a new manufacturing and quality centre in Hyderabad. This move aligns with Lilly’s broader global expansion, which includes a USD five billion investment in US facilities.
The launch of Lilly’s weight-loss drug Mounjaro in India has raised awareness of obesity treatments, a critical market as India is projected to have the world’s second-largest obese population by 2050.